Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases

RAD101 has a slightly better than even chance because this is a Phase 2b diagnostic imaging study, not a therapeutic efficacy test. The design is open-label, single-arm, and effectively within-subject against standard MRI, which lowers some sources of outcome variability and gives the sponsor room to frame lesion-level data favorably. The clinical setting is also real unmet need: after SRS/SRT, suspected recurrent brain metastases are difficult to assess on MRI alone, so a metabolic PET tracer has a plausible path to showing added value. The endpoint is relatively soft, focusing on concordance and lesions detected by PET/MRI but not MRI, rather than a hard survival or response outcome. That makes a positive readout more achievable, but also less definitive. Offsetting that, multicenter imaging studies are operationally tricky, lesion interpretation can be noisy, the population is heterogeneous across solid tumors, and no crisp success threshold is stated. The biggest caution is execution risk: the study is still recruiting despite an estimated January 1, 2026 primary completion date.

The second interim analysis (March 2026) already showed 90% (18/20) of evaluable patients achieved the primary endpoint of PET-MRI concordance, with significant selective tumor uptake in brain metastases. This is a diagnostic imaging concordance trial, not a therapeutic efficacy trial, which sets a structurally lower bar for success. The prior Phase 2a at Imperial College London also showed positive tumor uptake independent of tumor origin. FDA Fast Track designation further validates the unmet need and regulatory pathway. The first five patients with 6-month follow-up or biopsy show encouraging sensitivity/specificity trends on secondary endpoints. With two-thirds of the 30-patient study already reporting strong results, the remaining 10 patients would need to fail at an implausibly high rate to reverse the overall positive outcome. The full readout is expected by June 2026. The primary risk is that final compiled data could reveal unexpected discordance or the company applies an unexpectedly stringent statistical threshold, but given the strong interim signal and small trial size, this is unlikely.

This is a Phase 2b imaging study evaluating RAD101 (18F-FPIA) PET tracer for detecting recurrent brain metastases. The primary endpoint measures concordance between RAD101 PET/MRI and standard MRI with gadolinium - essentially a diagnostic accuracy comparison rather than a therapeutic efficacy trial. Phase 2b studies typically have moderate success rates, but imaging concordance studies face inherent variability depending on the specific concordance threshold defined as 'positive.' The single-arm, open-label design lacks randomization, and the outcome depends on achieving pre-specified sensitivity/specificity targets. With the primary completion date now passed (-91 days), results may be imminent, but the diagnostic endpoint makes outcome prediction inherently uncertain without disclosed performance thresholds. Given typical Phase 2 imaging study success rates and the technical challenges of PET/MRI concordance, intrinsic probability sits near even odds.

This is a Phase 2b diagnostic imaging study assessing concordance between a novel PET tracer (RAD101) and standard MRI for detecting recurrent brain metastases. The primary endpoint is descriptive (concordance metrics) rather than a superiority test against a control, which lowers the statistical hurdle for a 'positive' result. The single-arm, open-label design and use of standard-of-care follow-up for validation introduce operational and verification risks. However, prior Phase 1/2a data likely supported this study, and the sponsor (Radiopharm) has relevant theranostics expertise. The primary completion date has passed, suggesting data readout is imminent, but the 'Recruiting' status may indicate delays. Overall, the modest endpoint bar and plausible biological rationale support a slightly better-than-even chance of a positive readout, but the non-inferiority nature and validation method limit confidence.

This Phase 2b single-arm, open-label, multicenter imaging study evaluates RAD101 (18F-FPIA) PET/MRI versus gadolinium-enhanced MRI for detecting recurrent brain metastases from solid tumors. Primary endpoints measure concordance (number, size, proportion of SRS/SRT-treated lesions detected by both) and lesions uniquely identified by PET at 1 week, providing objective, quantifiable metrics ideal for imaging performance with minimal bias or placebo risk. Patient population (adults ≥18 with suspected recurrence) suits PSMA-targeted tracers, likely enriched for prostate cancer metastases despite broad 'solid tumors' label. Endpoint quality is high, clinically relevant for radiotherapy planning. Trial design avoids comparator arm pitfalls, focusing on detection superiority. No prior data specified, but Phase 2b implies Phase 1 success. Operational risks notable: recruiting status with primary completion overdue by 91 days (est. Jan 2026) signals enrollment/logistics delays in multicenter execution. Disclosure risk standard for small sponsor RADX. Strong setup favors positive concordance results, moderated by delays and potential PSMA expression variability.

This Phase 2b study (NCT06777433) evaluates RAD101 PET/MRI diagnostic performance in suspected recurrent brain metastases, a notoriously difficult clinical scenario where standard gadolinium MRI often cannot distinguish true tumor progression from post-treatment radiation necrosis. The primary endpoint focuses on concordance and lesion detection, which is a technically achievable bar for a novel amino acid PET tracer designed to detect active tumor metabolism. Prior Phase 1/2 data for similar F-18 labeled amino acid tracers (e.g., FET, FDOPA) have established strong proof-of-concept in this specific indication, supporting a favorable prior probability for RAD101's efficacy. The study design is open-label and single-arm, comparing RAD101 against the clinical reference standard, which mitigates operational execution risk. The primary completion date passed 91 days ago, suggesting data lock is imminent or complete. Given the high unmet medical need for better differentiation and the established mechanism class, the probability of a technically successful readout defining clinical utility is favorable.

Phase 2b imaging study of RAD101 in brain metastases with concordance endpoints against standard MRI. Single-arm design with objective imaging readouts reduces placebo risk. Primary completion was January 2026 (91 days past), suggesting data collection ongoing or near completion. PET tracer performance in brain metastases has precedent—18F-FDG PET limitations are known, creating opportunity for novel tracers. Concordance endpoints are measurable with clear success criteria. Small cap sponsor (RADX) introduces execution risk, but imaging studies have lower regulatory complexity than efficacy trials. Open-label design acceptable for imaging biomarker validation. No safety signal concerns in brief summary. Recruiting status with past primary completion date suggests potential data lock approaching. Disclosure risk moderate given small sponsor and imaging focus. Overall, technical success probability moderately favorable given objective endpoints and precedent for PET brain imaging agents.

The Phase 2b trial (NCT06777433) of RAD101 is evaluating its diagnostic performance in suspected recurrent brain metastases. The primary endpoint is the concordance between RAD101 PET/MRI and MRI with gadolinium. On March 24, 2026, Radiopharm Theranostics announced second interim results from 20 evaluable patients (out of a planned 30), explicitly stating they achieved the primary endpoint with 90% (18/20) concordance. They have already recruited 27 patients and plan to conclude the remaining enrollment shortly, with final top-line results expected around May or June 2026. Given the robust 90% concordance rate—which mirrors earlier interim data (92% concordance in Dec 2025)—and the company already preparing to discuss a Phase 3 design with the FDA based on these compelling metrics, the probability of a positive final readout is overwhelmingly high. The high tumor-to-background uptake ratio and lack of significant safety signals further derisk the final analysis. Final top-line results are imminent and highly likely to reflect these identical positive trends.

The Phase 2b imaging study of RAD101 in participants with suspected recurrent brain metastases appears to have a well-defined primary endpoint focused on concordance between RAD101 PET/MRI and MRI. The study's design, although single-arm, seems robust with a clear objective to establish imaging performance. Given that the indication targets a significant unmet need in brain metastases diagnosis and RAD101's novel approach, there's a reasonable basis for a positive outcome. However, the single-arm design and the relatively early stage of development introduce uncertainty.